Clinical Trial Research
Current Clinical Trials at Neuroscience Group
Migraines hurt all over, causing symptoms like debilitating headache, light sensitivity, sound sensitivity, and nausea. We’re studying an investigational treatment for the relief of migraine symptoms.
If you have been diagnosed with migraine, please learn more about the RELIEF research study. All study-related procedures and investigational drug are provided at no cost, and compensation will be provided to qualified candidates.
You may qualify to participate in the RELIEF study if you:
- Are 18 to 75 years of age
- Have experienced migraines for 1 year or more, starting before age 50
- Have had migraines on 4-15 days per month in each of the last 3 months
- Have migraines that, if left untreated:
- Cause headache pain of moderate to severe intensity as well as symptoms such as nausea, light sensitivity, or sound sensitivity
- Last between 4 and 72 hours
Other requirements may apply. For more information or to find out if you may be eligible to participate, please call our Clinical Research Coordinator at 920-239-8095 Ext: 1015.
Our office is currently participating in the Multiple Sclerosis clinical research trials/programs listed below. If you would like more information about any of these programs, speak with your provider to see if you may qualify for a current study or call our Clinical Research Coordinator at 920-239-8095 Ext. 1015 for more information.
PASSAGE: A world-wide study in patients who are starting new treatment for relapsing forms of multiple sclerosis (MS). Your participation in the study will provide an opportunity to learn more about the safety and satisfaction of MS treatments.
ESTEEM: A multicenter, global, observational study to collect information on safety and to document the drug utilization of Tecfidera™ (Dimethyl Fumarate) when used in routine medical practice in the treatment of multiple sclerosis (ESTEEM).
ASCLEPIOS: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.
Frequently Asked Questions
What are clinical trials?
Clinical trials are integral to medical advancement. These studies test new ways to prevent, detect, diagnose, or treat diseases and their goal is to determine if the new test or treatment is safe.
Who gets to be in a study?
Each research study is different. Each study tries to find answers to a specific question. Researchers must follow strict rules to decide who may take part in research. Not everyone with the disease or problem that is being studied can take part in a research study. If your doctor thinks that you might qualify for a study, he or she may ask if you want to take part.
Does Neuroscience participate in clinical trials?
We are currently participating in several clinical trials that are specific to MS drugs. We hope to have the opportunity to participate in trials for other conditions as well.
How can I participate in a clinical trial?
Speak with your provider to see if you may qualify for a current study or call our Clinical Research Coordinator at 920-239-8095 x 1015 for more information.
Are clinical trials safe?
The FDA works to protect participants in clinical trials and ensure that people have reliable information as they decide whether to join a clinical trial. The federal government has regulations and guidelines for clinical research to protect participants from unreasonable risks. Although efforts are made to control the risks to clinical trial participants, some risks may be unavoidable because of the uncertainty inherent in medical research studies involving new medical treatments.
What should I think about before joining a clinical trial?
People should learn as much as possible about the clinical trials that interest them. They should also feel comfortable discussing their questions and concerns with member of their health care team. Prospective participants should understand what happens during the trial, the type of health care they will receive and any costs to them—which may or may not include the cost of the product and costs associated with administering the product.